Mgenplus Co. Ltd. (032790) - Total Assets

Latest as of March 2026: ₩55.61 Billion KRW ≈ $37.69 Million USD

Based on the latest financial reports, Mgenplus Co. Ltd. (032790) holds total assets worth ₩55.61 Billion KRW (≈ $37.69 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 032790 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

Mgenplus Co. Ltd. - Total Assets Trend (2006–2025)

This chart illustrates how Mgenplus Co. Ltd.'s total assets have evolved over time, based on quarterly financial data. See net assets of Mgenplus Co. Ltd. for net asset value and shareholders' equity analysis.

Mgenplus Co. Ltd. - Asset Composition Analysis

Current Asset Composition (December 2025)

Mgenplus Co. Ltd.'s total assets of ₩55.61 Billion consist of 51.1% current assets and 49.0% non-current assets.

Asset Category Amount (KRW) % of Total Assets
Cash & Equivalents ₩0.00 21.8%
Accounts Receivable ₩5.19 Billion 8.7%
Inventory ₩3.73 Billion 6.2%
Property, Plant & Equipment ₩0.00 0.0%
Intangible Assets ₩3.35 Billion 5.6%
Goodwill ₩1.17 Billion 2.0%

Asset Composition Trend (2006–2025)

This chart illustrates how Mgenplus Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 032790 market cap.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Mgenplus Co. Ltd.'s current assets represent 51.1% of total assets in 2025, an increase from 0.0% in 2006.
  • Cash Position: Cash and equivalents constituted 21.8% of total assets in 2025, up from 2.7% in 2006.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 4.0% in 2006.
  • Asset Diversification: The largest asset category is accounts receivable at 8.7% of total assets.

Mgenplus Co. Ltd. Competitors by Total Assets

Key competitors of Mgenplus Co. Ltd. based on total assets are shown below.

Company Country Total Assets
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
USA $1.53 Billion
Abivax SA
PA:ABVX
France €584.34 Million
Akero Therapeutics Inc
NASDAQ:AKRO
USA $1.01 Billion
Chongqing Zhifei Bio Products
SHE:300122
China CN¥29.09 Billion
TELIX Pharmaceuticals Ltd
AU:TLX
Australia AU$1.19 Billion
INVENTIVA ADS/1 O.N.
F:6IVA
Germany €249.51 Million
Medincell SA
PA:MEDCL
France €74.58 Million
Alpha Tau Medical Ltd
NASDAQ:DRTS
USA $104.69 Million

Mgenplus Co. Ltd. - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.14 1.67 1.88
Quick Ratio 0.98 1.53 1.60
Cash Ratio 0.00 0.00 0.00
Working Capital ₩3.42 Billion ₩14.81 Billion ₩10.79 Billion

Mgenplus Co. Ltd. - Advanced Valuation Insights

This section examines the relationship between Mgenplus Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 0.97
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) -16.2%
Total Assets ₩59.85 Billion
Market Capitalization $17.49 Million USD

Valuation Analysis

Below Book Valuation: The market values Mgenplus Co. Ltd.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Mgenplus Co. Ltd.'s assets decreased by 16.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Mgenplus Co. Ltd. (2006–2025)

The table below shows the annual total assets of Mgenplus Co. Ltd. from 2006 to 2025.

Year Total Assets Change
2025-12-31 ₩59.85 Billion
≈ $40.56 Million
-16.21%
2024-12-31 ₩71.42 Billion
≈ $48.40 Million
+6.14%
2023-12-31 ₩67.29 Billion
≈ $45.60 Million
-11.41%
2022-12-31 ₩75.96 Billion
≈ $51.48 Million
+45.85%
2018-12-31 ₩52.08 Billion
≈ $35.29 Million
+44.70%
2017-12-31 ₩35.99 Billion
≈ $24.39 Million
+22.28%
2016-12-31 ₩29.43 Billion
≈ $19.95 Million
+7.97%
2015-12-31 ₩27.26 Billion
≈ $18.47 Million
-15.19%
2014-12-31 ₩32.14 Billion
≈ $21.78 Million
-21.78%
2013-12-31 ₩41.10 Billion
≈ $27.85 Million
-17.40%
2012-12-31 ₩49.76 Billion
≈ $33.72 Million
+5.03%
2011-12-31 ₩47.37 Billion
≈ $32.11 Million
+4.95%
2008-12-31 ₩45.14 Billion
≈ $30.59 Million
+5.61%
2007-12-31 ₩42.74 Billion
≈ $28.97 Million
-3.82%
2006-12-31 ₩44.44 Billion
≈ $30.12 Million
--

About Mgenplus Co. Ltd.

KQ:032790 Korea Biotechnology
Market Cap
$17.49 Million
₩25.81 Billion KRW
Market Cap Rank
#25515 Global
#1880 in Korea
Share Price
₩1005.00
Change (1 day)
+25.16%
52-Week Range
₩800.00 - ₩1090.00
All Time High
₩1090.00
About

Mgen Solutions Co., Ltd. engages in broadband communication network construction business. The company offers electricity, bio business and fire facility construction business, firefighting equipment and construction; printer developer; manufacturing and supply of electrical and electronic products such as transformers and inductors; artificial intelligence video analysis solution; printer develo… Read more